Moreno Sierra J, Blanco Jímenez E, Silmi Moyano A, Ortega Heredia M D, Páramo González P, Maestro de las Casas M L, Fernández Lucas C, Ramírez Fernández J C, Luengo Alpuente S, Gómez Vegas A
Cátedra y Servicio de Urología, Hospital Universitario San Carlos, Universidad Complutense, Madrid, España.
Arch Esp Urol. 1993 Nov;46(9):775-8.
The carbohydrate antigen CA 50 is expressed in the epithelial tissue during the process of neoplastic transformation; i.e., transitional cell bladder carcinoma. The present study evaluated the biological behaviour of the CA 50 antigen in malignant superficial, deep localized and disseminated bladder tumors. One hundred subjects were entered into the study: 30 carefully selected healthy subjects comprised the first group and 70 patients with a diagnosed transitional cell bladder carcinoma comprised the second group. The serum CA 50 antigen was determined by immunofluorometric assay (Delfia CA 50 kit). Our results indicate that the carbohydrate CA 50 antigen can be utilized as a prognostic marker in patients with malignant bladder tumors. The serum antigen levels were higher for the more undifferentiated tumors and those in the advanced stages.
碳水化合物抗原CA 50在肿瘤转化过程中在上皮组织中表达,即移行细胞膀胱癌。本研究评估了CA 50抗原在恶性浅表性、深部局限性和播散性膀胱肿瘤中的生物学行为。100名受试者进入研究:30名精心挑选的健康受试者组成第一组,70名诊断为移行细胞膀胱癌的患者组成第二组。血清CA 50抗原通过免疫荧光测定法(Delfia CA 50试剂盒)测定。我们的结果表明,碳水化合物CA 50抗原可作为恶性膀胱肿瘤患者的预后标志物。对于分化程度较低的肿瘤和晚期肿瘤,血清抗原水平较高。